Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edith A Perez

Showing results (11-20 of 324) with videos related to

Pageof 33
Sort By:
Clinical Advances in Hematology & Oncology : H&O|October 18, 2012
Highlights in metastatic breast cancer from the 2012 American Society of Clinical Oncology Annual MeetingEdith A Perez
The New England Journal of Medicine|June 3, 2005
TAC--a new standard in adjuvant therapy for breast cancer?Edith A Perez
The Oncologist|October 13, 2004
Carboplatin in combination therapy for metastatic breast cancerEdith A Perez
Clinical Breast Cancer|September 10, 2008
Cardiac toxicity of ErbB2-targeted therapies: what do we know?Edith A Perez
Seminars in Oncology|June 30, 2007
Novel enhanced delivery taxanes: an updateEdith A Perez
The Oncologist|November 18, 2006
Appraising adjuvant aromatase inhibitor therapyEdith A Perez
Clinical Advances in Hematology & Oncology : H&O|August 17, 2012
Next-generation targeted agents in HER2-positive metastatic breast cancerEdith A Perez
Clinical Breast Cancer|September 1, 2010
Challenges in applying recent clinical trial data to the care of patientsEdith A Perez
The Oncologist|February 1, 2011
Breast cancer management: opportunities and barriers to an individualized approachEdith A Perez
Current Oncology Reports|December 21, 2002
Adjuvant therapy approaches to breast cancer: should taxanes be incorporated?Edith A Perez
Pageof 33

Showing results (11-20 of 324) with videos related to

Sort By:
Pageof 33
Clinical Advances in Hematology & Oncology : H&O|October 18, 2012
Highlights in metastatic breast cancer from the 2012 American Society of Clinical Oncology Annual MeetingEdith A Perez
The New England Journal of Medicine|June 3, 2005
TAC--a new standard in adjuvant therapy for breast cancer?Edith A Perez
The Oncologist|October 13, 2004
Carboplatin in combination therapy for metastatic breast cancerEdith A Perez
Clinical Breast Cancer|September 10, 2008
Cardiac toxicity of ErbB2-targeted therapies: what do we know?Edith A Perez
Seminars in Oncology|June 30, 2007
Novel enhanced delivery taxanes: an updateEdith A Perez
The Oncologist|November 18, 2006
Appraising adjuvant aromatase inhibitor therapyEdith A Perez
Clinical Advances in Hematology & Oncology : H&O|August 17, 2012
Next-generation targeted agents in HER2-positive metastatic breast cancerEdith A Perez
Clinical Breast Cancer|September 1, 2010
Challenges in applying recent clinical trial data to the care of patientsEdith A Perez
The Oncologist|February 1, 2011
Breast cancer management: opportunities and barriers to an individualized approachEdith A Perez
Current Oncology Reports|December 21, 2002
Adjuvant therapy approaches to breast cancer: should taxanes be incorporated?Edith A Perez
Pageof 33